The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tabeeva G.R.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Sergeev A.V.

Chair of biophysical methods in medicine, Faculty of continuing medical education of the Russian University of Peoples’ Friendship;
G.N. Speransky Children's Clinical Hospital №9

Gromova S.A.

Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan)

Authors:

Tabeeva G.R., Sergeev A.V., Gromova S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(9): 32‑36

Read: 1347 times

Download PDF (RU)
Contact the author
Table of contents

POSSIBILITIES OF PREVENTIVE TREATMENT OF MIGRAINE WITH THE MT1- AND MT2 AGONIST AND 5-HT2С RECEPTOR ANTAGONIST AGOMELATIN (VALDOXAN)
POSSIBILITIES OF PREVENTIVE TREATMENT OF MIGRAINE WITH THE MT1- AND MT2 AGONIST AND 5-HT2С RECEPTOR ANTAGONIST AGOMELATIN (VALDOXAN)

To cite this article:

Tabeeva GR, Sergeev AV, Gromova SA. Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan). S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(9):32‑36. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Biochemical features of migraine pathogenesis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):21-26
Morning headaches in patients with obstructive sleep apnea syndrome: Pathogenesis, differential diagnosis, and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):92-97
Angiotensin model as a new approach to study of mese­nchymal stem cell sene­scence. Russian Cardiology Bulletin. 2025;(2):20-26
Complexity index of microsurgical treatment of unru­ptured cere­bral aneurysms. Burdenko's Journal of Neurosurgery. 2025;(3):28-41
Recu­rrent pain syndromes in adolescents of different ages. Russian Journal of Pain. 2025;(2):24-31
Prophylactic treatment of migraine in real clinical practice. Russian Journal of Pain. 2025;(2):63-69
Biofeedback in complex therapy of pain syndromes. Russian Journal of Pain. 2025;(2):70-75
Asso­ciations between sali­vary mela­tonin and periodontal disease: a systematic review and meta-analysis. Stomatology. 2025;(3):87-96
Complexity index of endo­vascular treatment of unru­ptured cere­bral aneurysms. Burdenko's Journal of Neurosurgery. 2025;(4):39-50
Vascular endo­thelial growth factor in episodic and chro­nic migraine: new approaches to unde­rstanding pathogenesis. Russian Journal of Pain. 2025;(3):17-21
Abstract:

Experimental and pilot clinical trials suggest the role of melatoninergic systems in the pathogenesis of migraine and the treatment effect of drugs acting on melatonin receptors. Authors studied the efficacy of the MT1- and MT2 agonist and selective 5-HT2C receptor antagonist agomelatine in the migraine prevention. Twenty patients with migraine, aged from 23 to 45 years, were treated with agomelatin in dose 25 mg per day during 3 months. The frequency of migraine attacks decreased from 7.4±2.4 to 3.8±1.4 (p=0.025), the duration and intensity of attacks decreased from 38.0±14.10 h to 24.0±6.1 h (p=0.018). The increase of treatment efficacy index, the decrease of headache impact on the general state measured with the VAS (from 8.1±1.8 to 7.2±1.6; p=0.01) and quality of life (HIT-6 index) as well as the duration of disability caused by headache (HALT index) were seen. The reduction of depression severity and normalization of night sleep were found in patients treated with agomelatin.

Keywords:

migraine
melatonin
agomelatin (valdoxan)
preventive treatment

Authors:

Tabeeva G.R.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Sergeev A.V.

Chair of biophysical methods in medicine, Faculty of continuing medical education of the Russian University of Peoples’ Friendship;
G.N. Speransky Children's Clinical Hospital №9

Gromova S.A.

Close metadata

References:

  1. Sergeev A.V., Tabeeva G.R., Azimova Yu.A. Tsentral'naya neironal'naya gipervozbudimost' - predispozitsiya k migreni. Ros zhurn boli 2010; 2: 27: 3-12.
  2. Tabeeva G.R. Khronobiologiya migreni. Zhurn nevrol i psikhiat 2010; 110: 4: 1: 104-112.
  3. Tabeeva G.R., Yakhno N.N. Migren'. M: GOETAR-Media 2011; 327-408.
  4. Tabeeva G.R., Sergeev A.V., Gromova S.V. Novye aspekty neirobiologii migreni: rol' gipotalamo-pineal'noi sistemy. Zhurn nevrol i psikhiat 2011;
  5. Claustrat B., Brun J., Geoffriau M. et al. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997; 17: 511-517.
  6. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
  7. Eser D., Baghai T.C., Moller H.J. Evidence of agomelatine's antidepressant efficacy: the key points. Int Clin Psychopharmacol 2007; 22: Suppl 2: 15-19.
  8. European Medicines Agency (2008). CHMP Assessment for Valdoxan. London 2008; Doc. Ref.: EMEA/655251/2008.
  9. Evers S., Afra J., Frese A. et al. EFNS guideline on the drug treatment of migraine. Eur J Neurol 2009; 16: 9: 968-981.
  10. Fornaro M., Prestia D., Colicchio S., Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8: 3: 287-304.
  11. Ghosh A., Hellewell J.S. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin Investig. Drugs 2007; 16: 1999-2004.
  12. Gori S., Morelli N., Maestri M. et al. Sleep quality, chronotypes and preferential timing of attacks in migraine without aura. J Headache Pain 2005; 6: 258-260.
  13. Hanoun N., Mocaer E., Boyer P.A. et al. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004; 47: 515-526.
  14. Headache Classification Committee of the International Headache Society. The international classification of headache disorders (2nd edition). Cephalalgia 2004; 24: Suppl 1: 1-160.
  15. Kasper S. Effect of agomelatine on rest-activity cycle in patients with major depressive disorder compared to sertraline. Int J Neuropsychopharmacol 2008; 11: Suppl 1: 193.
  16. Lemoine P., Guilleminault C., Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-1732.
  17. Millan M.J., Gobert A., Lejeune F. et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964.
  18. Montgomery S.A., Kennedy S.H., Burrows G.D. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280.
  19. Montgomery S.A., Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283-291.
  20. Nagtegaal J.E., Laurant M.W., Kerkhof G.A. et al. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J Psychosom Res 2000; 48: 45-50.
  21. Peres M.F., Sanchez del Rio M., Seabra M.L. et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001; 71: 747-751.
  22. Peres M.F.P. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005; 25: 403-411.
  23. Ramadan N.M. The link between glutamate and migraine. CNS Spectr 2003; 8: 446-449.
  24. Servier Laboratories Ltd., 2009. Valdoxan (agomelatine) Summary of Product Characteristics 2010. http://emc. medicines.org.uk /medicine/ 21830/SPC/Valdoxan/)
  25. Stahl S.M. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsycopharmacol 2007; 10: 575-578.
  26. Stovner L.J., Andree C. Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain 2008; 9: 3: 139-146.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.